Vimarsana
Biggest News Aggregation in the World

Page 17 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor) - Vimarsana News

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)

Investegate |Globaltrans Inv PLC Announcements | Globaltrans Inv PLC: Notification of Interim 2022 Results - Vimarsana News

Investegate |Globaltrans Inv PLC Announcements | Globaltrans Inv PLC: Notification of Interim 2022 Results

Investegate announcements from Globaltrans Inv PLC, Notification of Interim 2022 Results

FDA Granted Orphan Drug Designation to IMP4297+TMZ for SCLC - Vimarsana News

FDA Granted Orphan Drug Designation to IMP4297+TMZ for SCLC

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Junshi Biosciences Announces Acceptance of Supplemental - Vimarsana News

Junshi Biosciences Announces Acceptance of Supplemental

-- Additional indications: treatment for Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis and pediatric...

Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection - Vimarsana News

Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection

-- Additional indications: treatment for Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis and pediatric Crohn's disease SHANGHAI, China, Aug. 17, 2022